Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients
Background: Allogeneic hematopoietic stem cell transplantation (ASCT) induces acquired immunodeficiency, potentially altering vaccine response. Herein, we aimed to explore the clinical tolerance and the humoral and cellular immune responses following anti-SARS-CoV-2 vaccination in ASCT recipients. M...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/2/174 |
| _version_ | 1797296852235714560 |
|---|---|
| author | Ahmed Amine Ben Khlil Imen Zamali Dorra Belloumi Mariem Gdoura Ghassen Kharroubi Soumaya Marzouki Rym Dachraoui Insaf Ben Yaiche Soumaya Bchiri Walid Hamdi Manel Gharbi Ahlem Ben Hmid Samar Samoud Yousr Galai Lamia Torjmane Saloua Ladeb Jihene Bettaieb Henda Triki Nour Ben Abdeljelil Tarek Ben Othman Melika Ben Ahmed |
| author_facet | Ahmed Amine Ben Khlil Imen Zamali Dorra Belloumi Mariem Gdoura Ghassen Kharroubi Soumaya Marzouki Rym Dachraoui Insaf Ben Yaiche Soumaya Bchiri Walid Hamdi Manel Gharbi Ahlem Ben Hmid Samar Samoud Yousr Galai Lamia Torjmane Saloua Ladeb Jihene Bettaieb Henda Triki Nour Ben Abdeljelil Tarek Ben Othman Melika Ben Ahmed |
| author_sort | Ahmed Amine Ben Khlil |
| collection | DOAJ |
| description | Background: Allogeneic hematopoietic stem cell transplantation (ASCT) induces acquired immunodeficiency, potentially altering vaccine response. Herein, we aimed to explore the clinical tolerance and the humoral and cellular immune responses following anti-SARS-CoV-2 vaccination in ASCT recipients. Methods: A prospective, non-randomized, controlled study that involved 43 ASCT subjects and 31 healthy controls. Humoral response was investigated using the Elecsys<sup>®</sup> test anti-SARS-CoV-2. Cellular response was assessed using the QFN<sup>®</sup> SARS-CoV-2 test. The lymphocyte cytokine profile was tested using the LEGENDplex™ HU Th Cytokine Panel Kit (12-plex). Results: Adverse effects (AE) were observed in 69% of patients, encompassing pain at the injection site, fever, asthenia, or headaches. Controls presented more side effects like pain in the injection site and asthenia with no difference in the overall AE frequency. Both groups exhibited robust humoral and cellular responses. Only the vaccine transplant delay impacted the humoral response alongside a previous SARS-CoV-2 infection. Noteworthily, controls displayed a Th1 cytokine profile, while patients showed a mixed Th1/Th2 profile. Conclusions: Pfizer-BioNTech<sup>®</sup> anti-SARS-CoV-2 vaccination is well tolerated in ASCT patients, inducing robust humoral and cellular responses. Further exploration is warranted to understand the impact of a mixed cytokine profile in ASCT patients. |
| first_indexed | 2024-03-07T22:10:49Z |
| format | Article |
| id | doaj.art-1dc0a25183314d92bf79c3ab6c9b8ae5 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-07T22:10:49Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-1dc0a25183314d92bf79c3ab6c9b8ae52024-02-23T15:37:04ZengMDPI AGVaccines2076-393X2024-02-0112217410.3390/vaccines12020174Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant PatientsAhmed Amine Ben Khlil0Imen Zamali1Dorra Belloumi2Mariem Gdoura3Ghassen Kharroubi4Soumaya Marzouki5Rym Dachraoui6Insaf Ben Yaiche7Soumaya Bchiri8Walid Hamdi9Manel Gharbi10Ahlem Ben Hmid11Samar Samoud12Yousr Galai13Lamia Torjmane14Saloua Ladeb15Jihene Bettaieb16Henda Triki17Nour Ben Abdeljelil18Tarek Ben Othman19Melika Ben Ahmed20Department of Clinical Immunology, Institut Pasteur de Tunis, Tunis 1002, TunisiaDepartment of Clinical Immunology, Institut Pasteur de Tunis, Tunis 1002, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaLaboratory of Virology, Institut Pasteur de Tunis, Tunis 1002, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaLaboratory of Transmission, Control and Immunobiology of Infections (LR16IPT02), Institut Pasteur de Tunis, Tunis 1002, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaLaboratory of Transmission, Control and Immunobiology of Infections (LR16IPT02), Institut Pasteur de Tunis, Tunis 1002, TunisiaDepartment of Clinical Immunology, Institut Pasteur de Tunis, Tunis 1002, TunisiaLaboratory of Virology, Institut Pasteur de Tunis, Tunis 1002, TunisiaDepartment of Clinical Immunology, Institut Pasteur de Tunis, Tunis 1002, TunisiaDepartment of Clinical Immunology, Institut Pasteur de Tunis, Tunis 1002, TunisiaDepartment of Clinical Immunology, Institut Pasteur de Tunis, Tunis 1002, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaFaculté de Médecine de Tunis, Université Tunis El Manar, Tunis 1068, TunisiaDepartment of Clinical Immunology, Institut Pasteur de Tunis, Tunis 1002, TunisiaBackground: Allogeneic hematopoietic stem cell transplantation (ASCT) induces acquired immunodeficiency, potentially altering vaccine response. Herein, we aimed to explore the clinical tolerance and the humoral and cellular immune responses following anti-SARS-CoV-2 vaccination in ASCT recipients. Methods: A prospective, non-randomized, controlled study that involved 43 ASCT subjects and 31 healthy controls. Humoral response was investigated using the Elecsys<sup>®</sup> test anti-SARS-CoV-2. Cellular response was assessed using the QFN<sup>®</sup> SARS-CoV-2 test. The lymphocyte cytokine profile was tested using the LEGENDplex™ HU Th Cytokine Panel Kit (12-plex). Results: Adverse effects (AE) were observed in 69% of patients, encompassing pain at the injection site, fever, asthenia, or headaches. Controls presented more side effects like pain in the injection site and asthenia with no difference in the overall AE frequency. Both groups exhibited robust humoral and cellular responses. Only the vaccine transplant delay impacted the humoral response alongside a previous SARS-CoV-2 infection. Noteworthily, controls displayed a Th1 cytokine profile, while patients showed a mixed Th1/Th2 profile. Conclusions: Pfizer-BioNTech<sup>®</sup> anti-SARS-CoV-2 vaccination is well tolerated in ASCT patients, inducing robust humoral and cellular responses. Further exploration is warranted to understand the impact of a mixed cytokine profile in ASCT patients.https://www.mdpi.com/2076-393X/12/2/174COVID-19vaccineshumoral immunitycellular immunity |
| spellingShingle | Ahmed Amine Ben Khlil Imen Zamali Dorra Belloumi Mariem Gdoura Ghassen Kharroubi Soumaya Marzouki Rym Dachraoui Insaf Ben Yaiche Soumaya Bchiri Walid Hamdi Manel Gharbi Ahlem Ben Hmid Samar Samoud Yousr Galai Lamia Torjmane Saloua Ladeb Jihene Bettaieb Henda Triki Nour Ben Abdeljelil Tarek Ben Othman Melika Ben Ahmed Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients Vaccines COVID-19 vaccines humoral immunity cellular immunity |
| title | Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients |
| title_full | Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients |
| title_fullStr | Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients |
| title_full_unstemmed | Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients |
| title_short | Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients |
| title_sort | immunogenicity and tolerance of bnt162b2 mrna vaccine in allogeneic hematopoietic stem cell transplant patients |
| topic | COVID-19 vaccines humoral immunity cellular immunity |
| url | https://www.mdpi.com/2076-393X/12/2/174 |
| work_keys_str_mv | AT ahmedaminebenkhlil immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT imenzamali immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT dorrabelloumi immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT mariemgdoura immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT ghassenkharroubi immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT soumayamarzouki immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT rymdachraoui immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT insafbenyaiche immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT soumayabchiri immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT walidhamdi immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT manelgharbi immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT ahlembenhmid immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT samarsamoud immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT yousrgalai immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT lamiatorjmane immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT saloualadeb immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT jihenebettaieb immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT hendatriki immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT nourbenabdeljelil immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT tarekbenothman immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients AT melikabenahmed immunogenicityandtoleranceofbnt162b2mrnavaccineinallogeneichematopoieticstemcelltransplantpatients |